caa a22 4500 475833341 CHVBK 20180406123846.0 cr unu---uuuuu 170329e20001201xx s 000 0 eng 10.1023/A:1007827217400 doi (NATIONALLICENCE)springer-10.1023/A:1007827217400 Hypoglycemic Effect of Cibenzoline in Patients with Abnormal Glucose Tolerance and Frequent Ventricular Arrhythmias [Elektronische Daten] [Tetsunori Saikawa, Makoto Arita, Kohei Yamaguchi, Morio Ito] While some antiarrhythmic agents have potential hypoglycemic effects and indeed some reports of hypoglycemic adverse effect of those drugs, no systematic reports have been issued. We studied the hypoglycemic effects of cibenzoline, a class I antiarrhythmic agent. Cibenzoline succinate (150-300 mg/day) was given orally for 12 weeks to 10 patients who had ventricular premature complexes (VPCs) of <1000 per 24 hours and abnormal glucose tolerance before treatment with cibenzoline. Abnormal glucose tolerance, judged by a 75-g oral glucose tolerance test (OGTT), was defined as the response designated as "diabetic” or "borderline” type according to the criteria specified by the Japan Diabetes Society. In OGTT, the insulinogenic index (defined as the ratio of the increment of IRI [immunoreactive insulin] to that of plasma glucose at 30 minutes after a glucose load) and the sum of IRI (ΣIRI) were also determined. Holter ECG recordings, OGTT, and measurements of fasting plasma glucose IRI, and HbA1 c were performed before and during cibenzoline treatment. Cibenzoline caused VPC reduction of < 70% in 6 of the 10 patients. The drug significantly decreased fasting plasma glucose and HbA1 c (mean ± SD) 12 weeks after treatment, from 6.18 ± 0.92 mM/L to 5.54 ± 1.08 mM/L and from 6.17 ± 1.03% to 5.83 ± 0.96%, respectively (P < 0.05). While it significantly increased fasting IRI from 4.99 ± 1.50 to 6.51 ± 1.47 μU/mL (P < 0.01), the insulinogenic index from 0.33 ± 0.26 to 0.65 ± 0.38 (P < 0.05), and ∑ IRI from 168 ± 67 μU/mL to 199 ± 46 (P < 0.05). Cibenzoline exerted a hypoglycemic effect, facilitating insulin secretion in patients with abnormal glucose tolerance and ventricular arrhythmias. Kluwer Academic Publishers, 2000 cibenzoline nationallicence insulin secretion nationallicence insulinogenic index nationallicence hypoglycemic effect nationallicence ATP-sensitive K channel nationallicence arrhythmia nationallicence Saikawa Tetsunori Department of Laboratory Medicine, Japan aut Arita Makoto Department of Physiology II, Oita Medical University, Oita, Japan aut Yamaguchi Kohei First Department of Internal Medicine, Oita Prefectural Hospital, Oita, Japan aut Ito Morio Munakata Ishikairitsu Kensin Center, Japan aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/6(2000-12-01), 665-669 0920-3206 14:6<665 2000 14 10557 https://doi.org/10.1023/A:1007827217400 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007827217400 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Saikawa Tetsunori Department of Laboratory Medicine, Japan aut NATIONALLICENCE 700 1- Arita Makoto Department of Physiology II, Oita Medical University, Oita, Japan aut NATIONALLICENCE 700 1- Yamaguchi Kohei First Department of Internal Medicine, Oita Prefectural Hospital, Oita, Japan aut NATIONALLICENCE 700 1- Ito Morio Munakata Ishikairitsu Kensin Center, Japan aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/6(2000-12-01), 665-669 0920-3206 14:6<665 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer